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. These diseases are estimated to affect ~1 in 5,000 people worldwide and collectively represent the most common group of inherited metabolic disease 2 . Inherited mitochondrial diseases are caused by defects either in mitochondrial DNA (mtDNA), or in the nuclear genes encoding mitochondrial proteins 3 . These defects can affect the subunits of oxidative phosphorylation complexes, mtDNA translation and maintenance, mitochondrial assembly proteins and mitochondrial membrane composition. This Review focuses on endocrine dysfunction in primary genetic mitochondrial diseases, including discussion of the clinical features, genetic causes and underlying disease mechanisms.
Mitochondrial function
Mitochondria are dynamic cellular organelles with a multitude of functions, most notably the production of ATP, the unit of cellular energy, via oxidative phosphorylation. NADH and flavin adenine dinucleotide (FADH 2 ) are produced mainly in the Krebs cycle and from fatty acid oxidation (biochemical pathways that both take place within the mitochondrion) and fuel the respiratory chain complexes embedded in the inner mitochondrial membrane. Electrons from hydrogen are passed from complexes I and II to complex III, via the mobile electron carrier coenzyme Q 10 , then travel from complex III to a second mobile electron carrier (cytochrome c) and subsequently are transferred to complex IV, the terminal enzyme of the respiratory chain (FIG. 1) . Complexes I, III and IV act as proton pumps to generate an electrochemical gradient across the inner mitochondrial membrane. Finally, complex V (ATP synthase), which is powered by the electrochemical gradient, produces ATP from ADP and inorganic phosphate 4 . Other mitochondrial functions include calcium homeostasis, production of reactive oxygen species (which are essential cellular signalling molecules) regulation of apoptosis and the biosynthesis of all steroid hormones (including glucocorticoids, 2, 4 Abstract | Mitochondria are critical organelles for endocrine health; steroid hormone biosynthesis occurs in these organelles and they provide energy in the form of ATP for hormone production and trafficking. Mitochondrial diseases are multisystem disorders that feature defective oxidative phosphorylation, and are characterized by enormous clinical, biochemical and genetic heterogeneity. To date, mitochondrial diseases have been found to result from >250 monogenic defects encoded across two genomes: the nuclear genome and the ancient circular mitochondrial genome located within mitochondria themselves. Endocrine dysfunction is often observed in genetic mitochondrial diseases and reflects decreased intracellular production or extracellular secretion of hormones. Diabetes mellitus is the most frequently described endocrine disturbance in patients with inherited mitochondrial diseases, but other endocrine manifestations in these patients can include growth hormone deficiency, hypogonadism, adrenal dysfunction, hypoparathyroidism and thyroid disease. Although mitochondrial endocrine dysfunction frequently occurs in the context of multisystem disease, some mitochondrial disorders are characterized by isolated endocrine involvement. Furthermore, additional monogenic mitochondrial endocrine diseases are anticipated to be revealed by the application of genome-wide next-generation sequencing approaches in the future. Understanding the mitochondrial basis of endocrine disturbance is key to developing innovative therapies for patients with mitochondrial diseases.
Mitochondrial disease and endocrine dysfunction
mineralocorticoids, oestrogens, progesterone, androgens and calciferols) from cholesterol by specialized, tissue-specific mitochondrial enzymes 5 .
Mitochondrial genetics
Mitochondrial genetics is complicated by the contribution of two genomes: an intrinsic mitochondrial genome encoding 37 genes and the extrinsic nuclear genome, which contributes ~1,500 gene products targeted to the mitochondria, with 7% of the nuclear exome involved in producing these proteins 6 . The mitochondrial genome is a maternally inherited 16,569 bp circular doublestranded DNA molecule that encodes 13 subunits of oxidative phosphorylation proteins, as well as two ribosomal RNA and 22 transfer RNA (tRNA) molecules that are needed for the intramitochondrial synthesis of these 13 proteins on mitochondrial ribosomes. The nuclearencoded components of the mitochondrial proteome include proteins needed for replication, maintenance and expression of the mitochondrial genome, such as numerous transcription and translation factors and ~80 ribosomal proteins. Additionally, mitochondrial import proteins and enzymes involved in the Krebs cycle, fattyacid β-oxidation and biosynthesis of co factors and lipids, including the steroid hormones, are also encoded by nuclear genes 6 . Mutations in both mitochondrial and nuclear genomes have been linked to mitochondrial diseases, including maternally inherited point mutations and sporadic large-scale rearrangements of the mitochondrial genome. Next-generation sequencing methods have led to an enormous increase in nuclear gene defects found to result in mitochondrial diseases, with >250 genetic defects already described 7 . The majority of these nuclear defects are recessive, although some late-onset disorders are caused by dominant mutations and a few are X-linked (TABLE 1) . Thus, mitochondrial diseases can exhibit any mode of inheritance: maternal, autosomal dominant, autosomal recessive, X-linked or sporadic.
Mitochondrial genetics has some unusual properties. mtDNA is characterized by a very high copy number, with hundreds or thousands of copies in an individual cell. Consequently, a cell can be homoplasmic (in which 100% of the mtDNA copies within a cell are the same wild-type or mutant genotype) or heteroplasmic (in which mutant and wild-type mtDNA can coexist in the same cell) 8 . Almost all mtDNA mutations leading to mitochondrial disease result in a loss of function; for organ dysfunction to occur in the context of these disease-causing mutations, a minimum critical proportion of mtDNA has to be mutated in a tissue before a biochemical deficiency manifests 9 . Typically, the organs and tissues that are most affected are those with a high dependency on aerobic metabolism such as the brain, kidneys and heart 10 . However, mutant mtDNA hetero plasmy does not necessarily correlate with a patient's clinical manifestations. For example, evaluation of the amount of mutant mtDNA present in the sural nerve and thyroid gland of a patient with mitochondrial encephalo myopathy, lactic acidosis and stroke-like episodes (MELAS) showed >85% heteroplasmy, without clinical dysfunction of these tissues 11 . The reasons for the lack of correlation between heteroplasmy and phenotype are not completely understood, but could include different thresholds in different tissues or genetic, epigenetic or environmental modifiers. A functionally dominant mtDNA mutation (m.5545C>T in tRNA Trp ) caused severe multisystem disorder and respiratory chain deficiency at low levels of heteroplasmy (<25%) in affected tissues 12 .
Mitochondrial dysfunction
Mitochondrial dysfunction has been reported in a variety of heterogeneous diseases and theoretically can involve any combination of organ systems (FIG. 2) , as mitochondria are present in all cells except mature erythrocytes 13 . Although some mitochondrial disorders only affect a single organ, most involve multiple organ systems, with predominant neuromuscular and central nervous system features (including ptosis, external ophthalmoplegia, proximal myopathy, seizures, ataxia, optic atrophy and sensorineural hearing loss), as well as cardiomyopathy, renal dysfunction and hepatic impairment 1 . The incidence of endocrine dysfunction differs between different mitochondrial diseases, and seems to be most frequent in syndromes associated with large-scale rearrangements of the mtDNA. For example, in Kearns-Sayre syndrome (TABLE 1) , the frequency of endocrine disturbance has been reported to range from 35% to 67% 14, 15 . Kearns-Sayre syndrome is clinically characterized by a triad of progressive external ophthalmoplegia and pigmentary retinopathy with age of onset <20 years, and is variably associated with multisystem disease features such as cardiac conduction defects and cerebellar ataxia 16 . Other classic mitochondrial syndromes include maternally inherited diabetes mellitus and deafness (MIDD), myoclonic epilepsy with ragged-red fibres (MERRF) and MELAS, all of which are associated with point mutations in the mitochondrial genome (TABLE 1) .
Defective oxidative phosphorylation in mitochondrial diseases can lead to decreased intracellular production or extracellular secretion of hormones 17 . Impaired ATP synthesis decreases the activity of membrane
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Diabetes mellitus
Diabetes mellitus is the most well-described form of endocrine dysfunction in mitochondrial diseases. The association between mitochondrial disease and diabetes mellitus is best characterized in MIDD, a syndrome caused by the most common mtDNA point mutation m.3243A>G in MT-TL1 19 , which encodes a mitochondrial tRNA for leucine. This mutation is also associated with MELAS, and is present in 1 in 400 people within the general population 20 ; however, the majority of individuals with this mutation are asymptomatic or oligosymptomatic. The m.3243A>G mutation is estimated to cause ~0.5-2.9% of all cases of diabetes mellitus, with the prevalence being highest in patients from Japan at 2.9% 9, 19, [21] [22] [23] , making MIDD the most frequently reported form of diabetes mellitus resulting from mitochondrial genetic defects in the literature. Diabetes mellitus and multiple endocrinopathies are also observed in KearnsSayre syndrome, which is caused by large-scale mtDNA rearrangements 24, 25 . Other mtDNA mutations associated with diabetes mellitus include point mutations in the tRNA genes MT-TL1 (m.3254C>G, m.3256C>T, m.3264T>G, m.3271T>C), MT-TK (m.8344A>G, m.8356T>C), MT-TS2 (m.12258T>C) and MT-TE (m.14709T>C), as well as the m.14577T>C mutation in MT-ND6, which encodes NADH-ubiquinone oxidoreductase chain 6, a core subunit of complex I 22, [24] [25] [26] . Diabetes mellitus has also been reported in mitochondrial diseases caused by autosomal recessive mutations in the nuclear genes POLG, RRM2B, OPA1 and MPV17, all of which encode proteins implicated in mtDNA maintenance 9, 24, 27, 28 . Mitochondrial dysfunction can lead to type 1 or type 2 diabetes mellitus 19 , which can present insidiously at any age. The average age of onset is 38 years for the common m.3243A>G mutation, and ranges from 40 years to 56 years for other mutations 25 . Insulin deficiency has a major role in the development of diabetes mellitus, owing to progressive loss of β cells within the pancreas. The m.3243A>G mutation leads to mitochondrial dysfunction via a reduction in synthesis of mtDNAencoded proteins, which results in an imbalance within the mitochondrion between nuclear and mitochondrialencoded oxidative phosphorylation subunits 29, 30 . Furthermore, individuals with m.3243A>G and diabetes mellitus have combined insulin deficiency and insulin resistance 31, 32 . Additionally, patients with mitochondrial diabetes mellitus exhibit a high risk of progression to insulin dependency, which is not seen in patients with other forms of type 2 diabetes mellitus 9, 19, 25 . These findings provide further support for the theory of a combined insulin deficiency and resistance in mitochondrial diabetes mellitus 33 . In two studies, only 13% of patients with the m.3243A>G mutation and diabetes mellitus required insulin at presentation, with ~45% progressing to insulin dependence after a mean interval of 4.2 years in the first study 25 and 10 years in the second (reflecting the variability of mitochondrial disease) 34 . Pancreatic exocrine insufficiency is a frequent feature of Pearson syndrome (TABLE 1) 35 , an early-onset mtDNA deletion disorder. Insulin-dependent diabetes mellitus in neonates and infants has been described in some patients with Pearson syndrome, with or without concurrent exocrine pancreatic insufficiency 14 , in whom onset of diabetes mellitus ranged from the neonatal period up to 21 months [36] [37] [38] . Autopsy revealed fibrosis and atrophy of the exocrine and endocrine pancreas in two patients 37, 38 , and hypoplasia of the pancreas in one individual with diabetes mellitus but no symptoms suggestive of malabsorption 14 . Pattern recognition and a high level of clinical suspicion are crucial for identifying patients with diabetes mellitus caused by mitochondrial disease. Multi-systemic disease manifestations can precede onset of diabetes mellitus in patients with mitochondrial disease [39] [40] [41] [42] .
In addition to the pancreas, other organs with high metabolic activity are usually affected, including the brain, myocardium and kidneys 10 . For example, a combination of sensorineural deafness and a family history of maternal inheritance should raise suspicion that the patient might have a mitochondrial disease. Hearing loss in MIDD usually develops in early adulthood, and the most common ophthalmic feature is macular retinal dystrophy, observed in 86% of adult patients in a multicentre prospective study of MIDD 34 . Other clues pointing towards mitochondrial diabetes mellitus include a lower than average BMI compared with matched controls with type 1 or type 2 diabetes mellitus, (18.2 ± 2.3 versus 24.0 ± 3.6 kg/m 2 in patients requiring insulin at presentation; 20.9 ± 3.6 versus 30.2 ± 5.9 kg/m 2 in patients with type 2 diabetes mellitus at presentation) 25, 43 . Patients with the m.3243A>G mutation have not been found to carry islet cell or glutamic acid decarboxylase antibodies 9 , and the phenotype of diabetes mellitus in MIDD seems to be independent of HLA-DQ phenotype, unlike type 1 diabetes mellitus 44 . In a cohort of individuals from the UK, retinopathy, neuropathy and renal failure were more prevalent complications of diabetes mellitus in patients with m.3243A>G than in patients with type 1 or 2 diabetes mellitus who lacked the mutation 25 . Cardiac manifestations were also more frequent in patients with MIDD than in other patients with diabetes mellitus, including left ventricular hypertrophy in the absence of hypertension, cardiac autonomic neuropathy and reduced heart rate variability without coronary artery disease [45] [46] [47] [48] . This observation implies that pre-existent mitochondrial dysfunction in the end organs predispose individuals to these macrovascular and microvascular complications 9, 25 . As mentioned earlier in this article, patients with diabetes mellitus secondary to mtDNA mutations usually present with noninsulin-dependent diabetes mellitus, but a substantial proportion of these individuals rapidly progress to insulin dependency 9, 25 . The drug of choice for noninsulin-dependent diabetes mellitus is sulfonylurea 9 , because metformin and thiazolidinediones should ideally be avoided in patients with mitochondrial disease, as these drugs inhibit mitochondrial complex I and could worsen lactic acidosis 24, 49, 50 . End-organ involvement should be carefully monitored in patients with mitochondrial disease. With the high risk of renal involvement in mitochondrial disease, early use of angiotensin-converting-enzyme inhibitors and a tight control of hypertension is recommended 22 . Statins should be used judiciously in view of their potential for inducing myositis, and monitoring creatine kinase levels before and after treatment is recommended 9 .
Short stature Short stature is common in patients with mitochondrial diseases, and was present at diagnosis in 48% of a cohort of 96 patients with MELAS in Japan 41 . In this cohort, 55% of patients were diagnosed with short stature during their disease course. As might be expected, short stature was more common in patients with juvenile-onset MELAS than in patients with adultonset MELAS (60% versus 29%). Height and weight data of 24 children and adolescents in the UK with a confirmed diagnosis of mitochondrial disease revealed short stature (overall height standard deviation score (SDS) −1.97; 95% CI −2.72 to −1.23), and a low BMI (SDS −1.07; 95% CI −1.69 to −0.07) in these patients compared with UK normative data 51 . Faltering growth (defined as height below the 3 rd centile) was also noted in 28% of the Japanese MELAS cohort 41 . Although short stature can arise from any severe mitochondrial disease, with onset in infancy or early childhood, it occurs most frequently in association with cytochrome c oxidase (complex IV) deficiency, the causes of which include mutations in NDUFA4 (encoding cytochrome c oxidase subunit NDUFA4) and the assembly factors SURF1 (encoding surfeit locus protein 1), COX10 (encoding protoheme IX farnesyltransferase, mitochondrial, also known as cytochrome c oxidase assembly factor haem A: farnesyltransferase) and LRPPRC (encoding leucine-rich pentatricopeptide repeat containing protein, mitochondrial) [52] [53] [54] [55] . Growth failure (defined as growth parameters below the 3 rd centile) was reported in 95% of patients in a multicentre cohort of children diagnosed between birth and 30 months of age with Leigh syndrome secondary to surfeit locus protein 1 deficiency (that is, complex IV assembly defect) 54 , compared with 52% of patients with Leigh syndrome caused by LRPPRC mutations (leading to impaired mitochondrial translation of a complex IV subunit) 55 . Short stature is also recognized in KearnsSayre syndrome, with reported rates ranging from 38% to 63% 56, 57 . However, the precise mechanism for growth failure in these patients has not been well established.
Growth hormone deficiency has been described in multiple case reports and case series in patients with MELAS 11, [58] [59] [60] [61] [62] , mtDNA deletion disorders 14, 15, [63] [64] [65] [66] and various mitochondrial diseases with no causative mutation identified [67] [68] [69] . Growth hormone deficiency and/or short stature have also been documented in patients with nuclearencoded defects of mitochondrial translation, such as mutations in IARS2, MTFMT and C12orf65 .
Dysfunction of the hypothalamic-pituitary axis has been proposed as the mechanism for growth hormone deficiency in mitochondrial disease. Previous hypotheses for the underlying cause of hypothalamic dysfunction include chronic ischaemia and energy deficiency of the diencephalon owing to mitochondrial genetic abnormality of the hypothalamus or diencephalon 60 . One patient with MELAS and growth hormone deficiency had high (95%) levels of mutated mtDNA in the hypophysis 11 . This Figure 3 | The diagnosis of endocrine manifestations of mitochondrial disease. Genetic mitochondrial disease should be suspected in patients with endocrine dysfunction associated with multisystem disease. Patients can be referred to a specialist mitochondrial clinic for further investigations, including genetic testing. Ideally, patients with endocrine disturbance caused by a mitochondrial disease should be followed in both endocrine and mitochondrial disease clinics, and (if available) in a single multi-disciplinary clinic. *For example, m.3243A>G analysis in maternally inherited diabetes mellitus and deafness (MIDD) syndrome, or screen for mitochondrial DNA deletions in Kearns-Sayre syndrome. ‡ Examples of serum factors screened include cortisol, adrenocorticotropic hormone, parathyroid hormone, calcium ions, magnesium ions, phosphate ions and, in the case of short stature, insulin-like growth factor 1 and insulin-like growth-factor-binding protein 3.
patient also had anterior pituitary dysfunction in addition to hypothalamic impairment. Nonspecific neurodegenerative changes and cerebral atrophy were also reported in patients with mitochondrial disease and growth hormone deficiency 11, 15, 59 . In one patient with MELAS presenting with multiple endocrinopathies suggestive of hypothalamic dysfunction, the pituitary gland was normal despite severe cerebral and cerebellar atrophy 59 . By contrast, the only MRI abnormality observed in a 10-year-old boy with MELAS and complete growth hormone deficiency was bilateral T2-weighted hyperintense signal in the globus pallidus and in the midbrain tegmentum 65 . Drawing firm conclusions from these data is difficult, as the literature only contains single case reports, and no larger case series or cohorts have been published.
Most patients reported with confirmed growth hormone deficiency received growth hormone treatment as standard practice, and short-term improvement in growth has been noted without adverse effects 14, 58, 64, [67] [68] [69] . However, the long-term effects of growth hormone in this population are not clear 73 . Although most of the patients described did not report any adverse effects from growth hormone treatment, one study reported two of four patients whose condition worsened on growth hormone treatment. Of these patients, one individual with short stature only had low growth hormone secretion during sleep and had normal growth hormone secretion with provocation testing 69 . One patient developed hypotonia and loss of language and memory, and the other developed severe hypotonia, cerebellar ataxia and loss of speech and pyramidal signs after 3 months of treatment. Both patients showed improvement in their condition with discontinuation of growth hormone therapy. This result was hypothesized to be due to the stimulation of mitosis by growth hormone, which could increase energy demand for cell proliferation. However, drawing firm conclusions is difficult with such small numbers. Reports also exist of patients with growth hormone deficiency who did not respond to growth hormone treatment 69, 74 . Growth hormone deficiency has not been identified in some patients with mitochondrial dysfunction and short stature 15, 69, 75 . Many of these patients have delayed or absent puberty, which is also thought to contribute to the reported short stature, especially if they present during adolescence.
In summary, short stature is a common feature of mitochondrial disease, and growth hormone deficiency has been well described in patients with mitochondrial disease, particularly in mtDNA deletion syndromes and MELAS. However, many patients with short stature do not have growth hormone deficiency. Brain imaging findings are confounded by other pathologies that co-occur with growth hormone deficiency in patients with mitochondrial disease, and do not show pituitary abnormalities. Growth hormone therapy has been effective in improving height gain in some patients without adverse effects; however, efficacy is variable and, taking into consideration the potential adverse effects in patients with mitochondrial disease and short stature, we conclude that growth hormone should be used with caution in these patients and close monitoring is recommended.
Hypogonadism
Both hypergonadotropic hypogonadism and hypogonadotropic hypogonadism have been described in patients with mitochondrial disease. In a cohort of 21 patients with mitochondrial myopathy and external ophthalmoplegia, 38% were reported to have signs of hypogonadism 15 . Hypergonadotropic hypergonadism can also occur as a result of specific mitochondrial steroidogenic defects affecting the testis or ovaries (for example, mutations in STAR, CYP11A1 and HSD3B2), but detailed discussion of these conditions is beyond the scope of this Review 5, 76, 77 . Hypogonadotropic hypogonadism resulting from hypothalamic dysfunction has been more frequently described than primary ovarian or testicular insufficiency in patients with MELAS, MERRF or KearnsSayre syndromes, with poor development of secondary sexual characteristics and low serum concentrations of luteinizing hormone and follicle-stimulating hormone reported in these patients 15, 62, [78] [79] [80] [81] . Not all patients had delayed pubertal onset: in some patients a degree of pubertal development had occurred, who subsequently developed oligomenorrhoea or secondary amenorrhoea 15, 62, [78] [79] [80] [81] . Hypergonadotropic hypogonadism has been described in a mtDNA depletion syndrome caused by mutations in C10orf2 (encoding the twinkle protein, a mitochondrial DNA helicase) 82 . In a cohort of 23 patients with infantile-onset spinocerebellar ataxia caused by recessive C10orf2 mutations, two patients, both compound heterozygotes for the p.Y508C and p.A318T mutations, were noted to have hypergonadotropic hypogonadism by the time they were teenagers, alongside their neurological symptoms 82 . Other mitochondrial causes of hypergonadotropic hypogonadism include mutations in POLG [83] [84] [85] , mitochondrial neurogastrointestinal encephalomyopathy 86 , primary coenzyme Q 10 deficiency 87 , Leigh syndrome caused by a mutation in LRPPRC 55 and mutations in MRPS7, which encodes a mitochondrial ribosomal protein (reported in one patient) 88 . A novel disorder that has been termed an 'ovarioleukodystrophy' has also been linked to mutations in AARS2 (encoding mitochondrial alanyl-tRNA synthetase), in which all female patients with late-onset disease present with ovarian insufficiency, followed by progressive leukoencephalopathy 89 . Thus, all nuclear-encoded defects that result in hypergonadotropic hypogonadism seem to be associated with impaired mtDNA maintenance or gene expression.
In the context of mitochondrial disease, premature ovarian failure and premature menopause have been described most frequently in patients with the dominantly inherited POLG mutation p.Y955C 90 . Four women were described with progressive external ophthalmoplegia and early menopause (before the age of 35 years); a three generation pedigree with progressive external ophthalmoplegia and premature ovarian insufficiency has also been reported 83, 84 . Other mutations in POLG that are associated with premature ovarian failure in single patients include p.N468D 83 , p.A1105T 83 , p.R943H 85 and p.R953C 91 . Notably, all of these patients had accompanying neurological features, including parkinsonism, proximal muscle weakness and sensory ataxia, indicating that POLG mutations do not cause premature ovarian failure in isolation, but only in the context of a mitochondrial neurological disease.
Ovarian mtDNA deletion and menstrual irregularity has been observed in some women going through the menopause 92 . The mature oocyte has the highest mtDNA copy number of all cells 93 , and consequently could be more sensitive than other cells to reduced DNA polymerase γ activity 84 . An inadequate pool of primordial follicles, impaired oocyte maturation and accelerated follicle apoptosis owing to dysfunction of cytochrome c oxidase and increased production of reactive oxygen species have all been hypothesized to be the cause of ovarian insufficiency in natural ageing and menopause 94, 95 . Two studies sought to elucidate whether mutations in POLG could be responsible for isolated premature ovarian failure in a general population without features of mitochondrial disease. The first study evaluated 201 women with 46,XX and premature ovarian failure for five common POLG mutations associated with premature ovarian failure, and found only one woman with a POLG mutation (p.R943H) 91 . The second study did not identify any of four common POLG mutations in a cohort of 57 women with premature ovarian failure 90 . Thus, POLG mutations do not seem to be a common genetic aetiology for this form of infertility. Moreover, 13 of 14 women reported with POLG mutations and premature ovarian failure had associated neurological features (incomplete information is available for the 14 th case), which suggests that testing for POLG mutations is only indicated where clinical suspicion of a possible mitochondrial disorder exists 90, 96 Perrault syndrome is characterized by ovarian dysgenesis and sensorineural deafness 97 . Biallelic pathogenic variants have now been reported in five genes in individuals with Perrault syndrome 98 . Although the first reported variant in the gene HSD17B4 (which encodes a peroxisomal enzyme 17-β hydroxysteroid dehydrogenase type 4, involved in fatty-acid β-oxidation and steroid metabolism), the remaining four variants are found in genes that encode mitochondrial proteins. Three of these genes encode proteins that are involved in maintenance and expression of the mitochondrial genome: C10orf2 (REF. 99 ), HARS2 (encoding mitochondrial histidyl-tRNA synthetase) and LARS2 (encoding mitochondrial leucyl-tRNA synthetase) 97, [100] [101] [102] [103] . The fifth gene, CLPP, encodes ATP-dependent Clp protease proteolytic subunit, mitochondrial (also known as caseinolytic mitochondrial matrix peptidase proteolytic subunit) a serine protease that is an important component of the mitochondrial quality control system. Associated neurological symptoms in patients with CLPP mutations include truncal and cerebellar ataxia and lower limb spasticity 102, 103 . Patients with LARS2 mutations were reported to have normal neurological function and intelligence 101 . Mitochondrial dysfunction has been less frequently associated with fertility in men than in women in the literature. Both hypogonadotropic hypogonadism and hypergonadotropic hypogonadism have been described in men with mitochondrial neurogastrointestinal encephalomyopathy 80, 86 . POLG mutations were postulated to be a cause of infertility in men, but subsequent studies did not confirm an association between POLG mutations and oligo spermia or azoospermia [104] [105] [106] . No testicular dysfunction was observed in men with Perrault syndrome or AARS2 mutations, despite the presence of premature ovarian failure in women with the same mutations 89, 101 . In summary, hypogonadism can occur in patients with mitochondrial disease, manifesting either as hypothalamic dysfunction or as end-organ insufficiency. Premature ovarian failure can be the presenting feature of mitochondrial disease, preceding onset of neurological symptoms.
Adrenal dysfunction
Mitochondrial abnormalities of the adrenal axis were initially described in syndromes characterized by mtDNA deletion, such as Kearns-Sayre syndrome and Pearson syndrome 36, [107] [108] [109] [110] [111] . A total of 12 case reports identified primary adrenal insufficiency in 14 patients with genetically confirmed mitochondrial disease 112 , of whom five had Kearns-Sayre syndrome 17, [107] [108] [109] [110] , and two had Pearson syndrome 36, 111 . Primary adrenal insufficiency was subsequently reported in a 5-year-old child with a MELAS phenotype that was atypically associated with the m.8344A>G mutation (this mutation is more commonly associated with MERRF than MELAS) 113 . Several nuclear-encoded mitochondrial defects are associated with adrenal dysfunction. However, these defects do not primarily affect oxidative phosphorylation and a detailed Review of these conditions is provided elsewhere 5 ; therefore, they will only be discussed briefly here. Mutations in STAR (encoding steroidogenic acute regulatory protein, mitochondrial) affect cholesterol transport across the mitochondrial membrane and defects in CYP11A1 (encoding cholesterol side chain cleavage enzyme, mitochondrial) affect pregnenolone production 77, 114 . Severe defects in both these proteins lead to adrenal insufficiency, often with impaired gonadal sex steroid production. However, mutations leading to minor defects in these proteins can present with isolated adrenal insufficiency in childhood (before age 18 years) 115 . Other steroidogenic enzymes localised to the mitochondria are 3β-hydroxysteroid dehydrogenase, mitochondrial cytochrome P450 11B1 (also known as 11β-hydroxylase) and mitochondrial cytochrome P450 11B2 (also known as aldosterone synthase), which are involved in mineralocorticoid synthesis. Mutations in NNT, an antioxidant defence gene encoding nicotinamide nucleotide transhydrogenase, and TXNRD2, encoding mitochondrial thioredoxin reductase 2 (which is also part of the mitochondrial antioxidant defence system), have also been associated with familial glucocorticoid deficiency 116, 117 . In view of the severe nature of these defects, the fact that the only clinical manifestation was gluco corticoid deficiency in these patients is surprising. Further studies are needed to determine why the adrenal gland is particularly susceptible to oxidative stress and whether any other clinical features develop with time 118 .
Other nuclear-encoded genetic defects associated with adrenal insufficiency include defective complex I assembly resulting from NDUFAF5 mutations 119 , and abnormalities of mitochondrial translation, mitochondrial import and mtDNA replication. One of two sisters with mutations in MRPS7 (which encodes the mitochondrial 28S ribosomal protein S7 subunit) had primary adrenal insufficiency and primary hypogonadism at 16 years of age 88 . Adrenal insufficiency was also reported in a patient with combined respiratory complex deficiencies resulting from a homozygous QRSL1 mutation 7 . A 19-year-old woman with mitochondrial encephalopathy caused by mutations in GFER (encoding FAD-linked sulfhydryl oxidase ALR, a component of the mitochondrial protein import system) had primary adrenal insufficiency associated with congenital cataracts and lactic acidosis 112 . Finally, identical twins with a multisystem disorder, including polyendocrinopathy (diabetes mellitus, adrenal insufficiency and hypo thyroidism), bilateral basal ganglia infarcts, headaches, seizures and psychiatric problems, were reported to have a heterozygous POLG mutation p.G517V 27 . However, it has since been suggested that p.G517V is a neutral polymorphism as biochemical analysis of the mutant enzyme retained 80-90% of wild-type DNA polymerase activity and function 120 ; therefore, the underlying cause of mitochondrial disease in this family remains unclear.
Adrenal insufficiency with hyperpigmentation and hyponatraemia can be the first presenting symptom in mitochondrial disease before other symptoms appear, such as neurological symptoms, deafness and additional endocrine dysfunction 113, 121 . However, the age at onset of adrenal insufficiency varies widely, ranging from 7 months to 32 years, and can be preceded by other disease features 112 . Impaired mitochondrial ATP production and/or oxidative stress are the most probable explanations for the decreased capacity of adrenocortical hormone production in mitochondrial disease. A limited autopsy was performed in one patient with Kearns-Sayre syndrome who showed a trace amount of scar tissue replacing the adrenal glands 108 . Although adrenal insufficiency was a dominant feature in this patient, the percentage of mutant mtDNA was only 65% in the adrenal glands, compared with 95% in the liver, without any clinical hepatic disease 108 . Thus, the degree of mutant heteroplasmy among tissues does not necessarily correlate with clinical manifestations.
Hypothalamic-pituitary dysfunction as a cause of secondary cortisol insufficiency has only been reported once in a patient with MERRF 122 . Growth hormone and gonadotropins seem to be the predominant hormonal deficits in patients with a mitochondrial disorder and pituitary or hypothalamic dysfunction.
Hypoparathyroidism
Although hypoparathyroidism is not common in mitochondrial disease overall, this disease is known to occur and is more frequently observed in KearnsSayre syndrome. A literature survey conducted in 1992 retrospectively reviewed endocrine dysfunction in 226 patients fitting the criteria for Kearns-Sayre syndrome 57 . Hypoparathyroidism was present in 14 of 226 (6%) patients; however, a mixture of probable cases and a small number of cases with onset after the age of 20 years were included. In a subsequent series, three of 34 (9%) children with single mtDNA deletion disorders had hypoparathyroidism 14 . In two patients with Kearns-Sayre syndrome and hypoparathyroidism, one patient was found to have no parathyroid glands at autopsy 123 , and the other had only one parathyroid gland confirmed by microscopic examination 124 . Four children with Kearns-Sayre syndrome presented with hypoparathyroidism and deafness as the initial major manifestations, with hypocalcaemic tetany starting between the ages of 6 years and 13 years 125 . Deafness preceded the onset of hypoparathyroidism in two patients. In another patient with Kearns-Sayre syndrome, hypoparathyroidism was the initial presentation at 3 years of age, before onset of growth failure and hearing deficit 126 . Other patients had other accompanying features including growth failure and neurological symptoms, ptosis, ophthalmoplegia, myopathy and sensorineural hearing loss 17, 57, 127 . Renal tubulopathy is common in patients with Kearns-Sayre syndrome and other mitochondrial disorders, leading to considerable loss of calcium, magnesium and potassium in the urine 14, [128] [129] [130] . In a retrospective review of patients with single mtDNA deletion disorders, 14 of 20 patients had abnormal elevation of urinary tubulopathy markers retinol bind protein or N-acetyl-3-glucosaminidase 14 . Severe hypomagnesaemia suppresses parathyroid hormone secretion and could induce some parathyroid hormone resistance, leading to further hypocalcaemia 131 . In two patients with Kearns-Sayre syndrome, parathyroid hormone concentrations remained low despite magnesium supplementation 128, 132 . Coexisting renal tubular dysfunction and hypoparathyroidism could contribute to disturbances in calcium homeostasis in patients with Kearns-Sayre syndrome. In addition to Kearns-Sayre syndrome, hypoparathyroidism has been documented in one patient with MIDD with the m.3243A>G mutation in MT-TL1 (REF. 133 ).
Multiple endocrinopathies have been documented in case reports of patients with Kearns-Sayre syndrome and hypoparathyroidism, particularly in association with diabetes mellitus 42, 125, 126, 134 . Three of 34 patients with single mtDNA deletion disorders had hypoparathyroidism 14 . Hypoparathyroidism tends to occur in patients severely affected with mitochondrial disease who present with multisystemic disease in childhood 9 . The investigators in this study hypothesized that the heteroplasmic threshold for dysfunction of the parathyroid gland is only reached in patients with very high levels of heteroplasmy in most tissues. The incidence of other endocrine abnormalities was also more frequent in Kearns-Sayre syndrome patients with hypoparathyroidism versus those without hypoparathyroidism, including diabetes mellitus (28% versus 12%), thyroid disease (14% versus 2%) and hypogonadism (35% versus 18%); however, the sample sizes were too small to reach robust conclusions 57 . In summary, mitochondrial hypoparathyroidism is associated with severe multisystem disease and is often seen in combination with other endocrinopathies in Kearns-Sayre syndrome.
Thyroid disease
Thyroid dysfunction has been infrequently reported in mitochondrial disease 9 . Numerous case reports have documented hypothyroidism developing in a heterogeneous group of patients, including 15% (six of 40) of an adult cohort with late-onset chronic progressive external ophthalmoplegia, and was more frequent than diabetes mellitus (5%) in this cohort 135 . Hypothyroidism has been described in patients with mtDNA deletions, including Kearns-Sayre syndrome 14, 57, 63 . In a 1992 literature review, seven of 226 patients (3%) with probable Kearns-Sayre syndrome had thyroid disease 57 . Types of thyroid dysfunction reported include compensated hypothyroidism, multinodular goitre, congenital thyroid malformation and papillary carcinoma. Central hypothyroidism has also been described in a patient with MELAS 62 . Very few nuclear-encoded mitochondrial defects have been linked to thyroid dysfunction. As discussed earlier in this article, a polyendocrinopathy including diabetes mellitus, adrenal insufficiency and hypothyroidism was reported in twins with a heterozygous POLG mutation p.G517V 27 , but the pathogenic relevance of this mutation has since been questioned, in the context of adrenal insufficiency 120 . Recessive mutations in PTRH2, encoding mitochondrial peptidyl-tRNA hydrolase 2, have been associated with a complex multisystem disorder including hypothyroidism and exocrine pancreatic insufficiency that is associated with intellectual disability, microcephaly, progressive ataxia, distal muscle weakness, peripheral demyelinating sensorimotor neuro pathy, growth retardation, sensorineural deafness and liver fibrosis 136 . In summary, although thyroid dysfunction is common in the general population globally, whether any causal relationship exists between mitochondrial disease and thyroid dysfunction is currently unknown. Inadequate data exists to determine whether thyroid dysfunction occurs more frequently in mitochondrial disease than in the background population. However, as subclinical hypothyroidism can be asymptomatic 137 , the incidence of hypothyroidism is probably underestimated in this group of patients.
Conclusions
Mitochondrial diseases are multisystemic diseases that can present with endocrine dysfunction, most notably in the mtDNA deletion syndromes such as Kearns-Sayre syndrome and disorders associated with mtDNA point mutations affecting tRNA genes, such as MIDD, MELAS and MERRF. Endocrine dysfunction has been reported in a large number of nuclear-encoded mitochondrial defects, most frequently in those affecting maintenance of mtDNA or mitochondrial translation. The underlying disease mechanisms that lead to mitochondrial endocrine dysfunction remain obscure. Failure to synthesize and/or secrete hormones, secondary to lack of ATP and/or oxidative stress, have been implicated in the pathogenesis of mitochondrial endocrine dysfunction, but other possible mechanisms include impaired cellular signalling and calcium handling. Further studies in animal and patient cell models of mitochondrial disease are needed to characterize these mechanisms in more detail.
Diabetes mellitus is well recognized in mitochondrial diseases, especially in MIDD. Gonadal insufficiency, and most frequently ovarian insufficiency, has also been reported in various mitochondrial disorders. Other types of end-organ dysfunction such as primary adrenal insufficiency and hypoparathyroidism are less frequently described than diabetes mellitus or ovarian dysfunction. Multiple endocrinopathies can include hypothalamic dysfunction with multiple pituitary hormone deficiencies. Patients with hypoparathyroidism and primary adrenal insufficiency have also been found to have other endocrinopathies.
Endocrine dysfunction can be the initial presenting symptom preceding hearing impairment and other neurological manifestations of mitochondrial diseases. Physicians should have a high level of suspicion in patients presenting with endocrine abnormalities and multisystemic diseases for the possibility of an underlying mitochondrial disease (FIG. 3) . Equally, physicians managing patients with mitochondrial diseases should be aware of possible multiple-endocrine complications and regularly screen for them in at-risk patients, given that these are potentially treatable aspects of these incurable disorders.
